Standout Papers

Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer 2000 2026 2008 2017 2.3k
  1. Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer (2000)
    Leonard B. Saltz, John V. Cox et al. New England Journal of Medicine
  2. Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor (2003)
    Michael C. Heinrich, Christopher L. Corless et al. Journal of Clinical Oncology
  3. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial (2009)
    Ronald P. DeMatteo, Karla V. Ballman et al. The Lancet
  4. Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033 (2008)
    Charles D. Blanke, Cathryn Rankin et al. Journal of Clinical Oncology
  5. Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT (2008)
    Charles D. Blanke, George D. Demetri et al. Journal of Clinical Oncology
  6. Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors (2006)
    Michael C. Heinrich, Christopher L. Corless et al. Journal of Clinical Oncology
  7. Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection (2012)
    Stephen R. Smalley, Jacqueline Benedetti et al. Journal of Clinical Oncology
  8. Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials (2005)
    Daniel J. Sargent, Harry S. Wieand et al. Journal of Clinical Oncology
  9. Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205 (2010)
    Philip A. Philip, Jacqueline Benedetti et al. Journal of Clinical Oncology
  10. Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group (2008)
    Michael C. Heinrich, Kouros Owzar et al. Journal of Clinical Oncology

Immediate Impact

3 by Nobel laureates 8 from Science/Nature 148 standout
Sub-graph 1 of 13

Citing Papers

Colorectal cancer
2024 Standout
Diagnosis and Treatment of Metastatic Colorectal Cancer
2021 Standout
34 intermediate papers

Works of Charles D. Blanke being referenced

Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
2016
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
2014
and 10 more

Author Peers

Author Last Decade Papers Cites
Charles D. Blanke 8311 9402 5677 6389 288 18.1k
John Zalcberg 9455 7808 5365 2801 398 18.1k
Patrick Schöffski 9407 9276 3130 2595 500 18.9k
Peter W. T. Pisters 16521 17018 10962 4080 293 26.7k
Daniel G. Haller 16480 8996 8552 1696 242 24.7k
Paolo G. Casali 8147 18356 5257 6359 424 24.0k
Narikazu Boku 7970 9797 6197 3043 538 14.9k
John S. Macdonald 11271 9680 7266 1754 170 19.3k
Olivier Bouché 18148 9242 7789 1945 410 24.6k
Valérie Boige 9238 6005 5539 1050 282 17.2k
David P. Kelsen 8708 6226 4144 1059 290 14.4k

All Works

Loading papers...

Rankless by CCL
2026